Cash cost of the wait: management is funding a defined waiting period whose end is already scheduled
The model's full reasoning — Q3 2018 call → NOWe need to determine if the company is currently living through a defined waiting period it is paying for out of its own pocket, with a specific near-dated event that ends the wait, and that this is the main current work. Let's analyze the transcript. The question asks: "On this call, does management describe the company as CURRENTLY LIVING THROUGH A DEFINED WAITING PERIOD IT IS PAYING FOR OUT OF ITS OWN POCKET — that is, does management convey that the company is presently carrying real, ongoing cash or earnings cost for something whose benefit has not arrived yet, AND that the end of that waiting period is a specific, near-dated event the company can already see and is already working toward?" We need to find if management describes such a situation. Look for mentions of costs being incurred now for future benefits, with a specific near-term event. Possible candidates: - Biosimilars: They have launched KANJINTI and AMGEVITA, but they are already launched, so not waiting. - Pipeline: They have many programs in development, but that's normal R&D investment, not a defined waiting period with a specific near-dated event. - Repatha: They lowered price to improve access, but that's a pricing decision, not a waiting period. - Aimovig: They are investing in launch, but that's already launched and generating revenue. Look for something like "we are paying for X now, and we expect Y to happen soon." For example, they mention "we are preparing our US and EU regulatory submissions for ABP 710, our biosimilar Remicade which we expect to occur by the first quarter of next year." That is a submission, not a revenue event. Also, they have "ABP 959, our biosimilar Soliris" in Phase 3 start-up. But these are not described as a waiting period with costs being borne now. Another possibility: They mention "we are in start-up of the Phase 3 pivotal study" for ABP 959. But that's R&D. The question specifically asks about a "defined waiting period" where the company is paying for something not yet earning, and the end is a specific near-dated event. Management should convey that this is the main current work. Look at the transcript: There is no explicit mention of a situation where they are incurring costs for a future benefit that is near-dated. They talk about investments in launches, but those are already generating revenue. They talk about pipeline, but that's long-term.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| KOPN | Kopin Corporation | Q4 2023 | 2024-03-14 | C+ |
| LILA | Liberty Latin America Ltd. | Q4 2023 | 2024-02-23 | C |
| SBS | Companhia de Saneamento Básico do Estado | Q3 2023 | 2023-11-10 | C+ |
| QTRX | Quanterix Corporation | Q3 2023 | 2023-11-07 | B |
| APPS | Digital Turbine, Inc. | Q1 2024 | 2023-08-08 | D |
| PRPH | ProPhase Labs, Inc. | Q1 2023 | 2023-05-11 | F |
| CDE | Coeur Mining, Inc. | Q1 2023 | 2023-05-11 | C+ |
| SOL | ReneSola Ltd | Q3 2022 | 2022-12-01 | C+ |
| FLL | Full House Resorts, Inc. | Q3 2022 | 2022-11-07 | B |
| EHTH | eHealth, Inc. | Q2 2021 | 2021-07-29 | F |
| IRT | Independence Realty Trust, Inc. | Q2 2018 | 2018-08-02 | B |
| YUM | Yum! Brands, Inc. | Q2 2018 | 2018-08-02 | C |
| IBTX | Independent Bank Group, Inc. | Q3 2017 | 2017-10-24 | A |
| FLEX | Flex Ltd. | Q1 2018 | 2017-07-28 | F |
| DAN | Dana Incorporated | Q1 2017 | 2017-05-02 | B |
SBS · Q3 2023 → YESThe question is whether management describes the company as currently living through a defined waiting period it's paying for out of its own pocket. YES The transcript shows management describing the company as currently bearing real, ongoing cash costs (salaries, consulting, transition work) for the IDP/restructuring program whose benefits (full expense reduction, shared-services center operational) are not yet realized. The far side is a specific, near-dated event: full 3.7% staff reduction and shared-services center operational by mid-2024 (July 2024 for full benefit), with the program already in motion and on schedule. Management frames this as the main current work, not a setback, and treats the costs as self-funded. This meets all three conditions.
EHTH · Q2 2021 → YESThe question is whether management describes the company as currently living through a defined waiting period it is paying for out of its own pocket. YES The transcript shows management describing the company as currently living through a defined waiting period for the AEP, paying for it out of its own pocket through heavy investments in internal agents and quality initiatives. They hired agents early, many still in training with lower productivity, and are bearing the cost of additional training and customer service expansion in Q3. This is framed as a chosen investment to improve enrollment quality and prepare for the fourth-quarter AEP, not an apology or external issue.
YUM · Q2 2018 → YESThe question is whether management describes the company as currently living through a defined waiting period it is paying for out of its own pocket. YES The transcript shows management describing a clear, self-funded transition cost tied to the refranchising effort. They explicitly call out the “timing mismatch between G&A savings and refranchising” as one of the four items weighing on Q2 core operating profit, and they quantify the full-year headwind at 6 7 percentage points. This is presented as a real, ongoing drag on current results while they complete the shift to 98 % franchised by year-end 2018 and reach the 1.7 % G&A run-rate target in 2019.